DNLI vs TARS: stock comparison and AI forecast
Denali Therapeutics Inc. (DNLI) and Tarsus Pharmaceuticals, Inc. (TARS) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
DNLI Denali Therapeutics Inc.
- Market Cap
- $3.03B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
- NO CURRENT FORECAST
TARS Tarsus Pharmaceuticals, Inc.
- Price
- $74.20 +16.6% · 6M
- Market Cap
- $3.26B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
- NO CURRENT FORECAST
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- DNLI and TARS have similar market capitalizations ($3.03B and $3.26B).
- TARS turns -7.7% of its revenue into net income, against -14191.2% for DNLI.
- TARS carries 0.76 times debt per unit of equity, against 0.39 times for DNLI.
- Both companies share the SEC industry classification Biological Products, (No Diagnostic Substances).
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | DNLI | TARS |
|---|---|---|
| Market Cap | $3.03B | $3.26B |
| P/B Ratio | 3.62x | 9.39x |
| EPS | $-2.93 | $-1.54 |
| Book Value/Share | $5.22 | $7.90 |
| Revenue/Share | – | $13.82 |
| FCF/Share | $-2.74 | $1.28 |
Profitability & Margins
| Metric | DNLI | TARS |
|---|---|---|
| ROE | -61.2% | -13.4% |
| ROA | -44.2% | -7.6% |
| ROIC | -50.8% | -11.2% |
| Operating Margin | -15058.2% | -8.0% |
| Net Margin | -14191.2% | -7.7% |
| EBT Margin | -15058.2% | -5.9% |
| Tax Rate | -0.0% | -19.9% |
Financial Health
| Metric | DNLI | TARS |
|---|---|---|
| Current Ratio | 8.37x | 3.20x |
| Quick Ratio | 8.32x | 3.17x |
| D/E Ratio | 0.39x | 0.76x |
| Financial Leverage | 1.39x | 1.76x |
| Interest Coverage | – | -9.2x |
| Working Capital | $664M | $386M |
Cash Flow
| Metric | DNLI | TARS |
|---|---|---|
| Operating Cash Flow | -$434M | $74M |
| Free Cash Flow | -$437M | $56M |
| Capital Spending | -$3M | -$18M |
| FCF/Sales | – | 9.2% |
| CapEx/Sales | – | 3.0% |
Operational Efficiency
| Metric | DNLI | TARS |
|---|---|---|
| Asset Turnover | – | 0.99x |
| Receivables Turnover | – | 6.3x |
| Fixed Assets Turnover | – | 29.6x |
| Days Sales Outstanding | – | 58 days |
Income Statement
| Metric | DNLI | TARS |
|---|---|---|
| Total Revenue | – | $606M |
| Operating Income | -$543M | -$49M |
| Net Income | -$511M | -$46M |
| R&D Expense | $401M | $88M |
| SG&A Expense | – | $526M |
Dividend & Shareholder Information
| Metric | DNLI | TARS |
|---|---|---|
| Shares Outstanding | 160M | 44M |
DNLI vs TARS: stock comparison and AI forecast
Which is bigger, DNLI or TARS?
DNLI and TARS have similar market capitalizations ($3.03B and $3.26B).
Which one does Intratio's AI model rank higher, DNLI or TARS?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.